The 2025 European Hematology Association (EHA) Annual Meeting was recently held, bringing together top global experts in the field of hematologic malignancies to discuss the latest research findings and future directions. In the highly anticipated "Late-Breaking Abstract" session, Professor John Mascarenhas from the Icahn School of Medicine at Mount Sinai presented clinical study data on INCA33989, a novel, first-in-class monoclonal antibody specific to mutant calreticulin (CALR). The study results showed that INCA33989 demonstrated excellent safety and revolutionary therapeutic potential in previously treated patients with Essential Thrombocythemia (ET), with the potential to change the current treatment landscape

Editor's Note: With advancements in medicine, allogeneic hematopoietic cell transplantation (allo-HCT) has become a hope for a cure for many patients with high-risk hematologic malignancies. However, the high risks and…

Editor's Note: From June 12 to 15, 2025, the European Hematology Association (EHA) Annual Congress was held in Milan, Italy, bringing together top experts in the field of hematology from…

Editor's Note: At the 2025 European Hematology Association (EHA) Annual Congress, a dedicated guideline session was grandly held, bringing together top experts in the global hematology field. One of the…

Editor's Note: At the European Hematology Association (EHA) 2025 Annual Congress, the special session on Multiple Myeloma (MM) was filled to capacity. The core focus of the meeting was the…

Editor's Note: During the 2025 European Hematology Association (EHA) Annual Meeting, a session on the interpretation of the new Peripheral T-Cell Lymphoma (PTCL) guidelines drew significant attention. At this session,…

Editor's Note: In 2025, the highly anticipated 30th European Hematology Association (EHA) Annual Congress was grandly held in Milan, Italy. This conference brought together top experts and scholars from around…

Editor's Note: In 2025, the highly anticipated 30th European Hematology Association (EHA) Annual Meeting was grandly held in Milan, Italy in a combination of online and offline formats. Professor Johanna…

Editor's Note: At the recent European Hematology Association (EHA) Annual Congress, a premier event held in Milan, Italy, top global experts in hematology convened to discuss cutting-edge diagnostic and therapeutic…

The 2025 European Hematology Association (EHA) Annual Meeting was grandly held both online and in-person, gathering top experts and scholars from the global hematology community. During the highly anticipated Presidential Symposium, Professor Nicola Cooper, an immune-hematologist from Imperial College London, delivered a keynote speech on "Immune Thrombocytopenia (ITP): From Biology to Targeted Therapy." She systematically reviewed the century-long evolution of ITP from its initial recognition to modern treatment, and by focusing on cutting-edge research, she outlined a clear roadmap for the future of personalized, precision therapy.